Elizabeth LindquistPartner at Arnold & Porter
Liz Lindquist counsels drug, biologic and medical product manufacturers, distributors and investors, among other life sciences industry stakeholders, on a broad range of regulatory, compliance, transactional, investigation, litigation, and legislative issues involving federal and state government healthcare agencies and enforcement authorities. Her practice focuses in part on advising clients on complex drug price calculations and related reporting and contracting matters.
Throughout the COVID-19 pandemic, Liz has represented numerous clients in a wide variety of federal procurement and contracting matters, including extensive work pertaining to the US government’s invocation of the Defense Production Act (DPA) and use of other emergency contracting procedures. She provides strategic counsel on federal funding and procurement opportunities and related interactions with Congress and key federal officials, agencies and task forces involved in pandemic response and future preparedness efforts, including the White House COVID-19 Task Force, the US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA), and US Department of Defense procurement authorities. Liz is also well versed in federal and state “Buy American” (i.e., domestic preference) policies and initiatives, developing and implementing clients’ government-advocacy strategies around the potential business opportunities and risks associated with the onshoring of essential medical supply chains.